Tefibazumab (marketed under the brand name Aurexis) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in patient with cystic fibrosis[1] and of methicillin-resistant S. aureus.[2]
It was developed by Inhibitex.[3]
[edit] See also
- MSCRAMM (microbial surface components recognizing adhesive matrix molecules)
[edit] References
- ^ ClinicalTrials.gov NCT00198289
- ^ Pan; Lorenzotti, S.; Zoncada, A. (2008). "Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection". Recent patents on anti-infective drug discovery 3 (1): 10–33. doi:10.2174/157489108783413173. PMID 18221183. edit
- ^ John JF (2006). "Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection". Curr. Opin. Mol. Ther. 8 (5): 455–60. PMID 17078388.
|
|
|
| Fungal ("-fung-") |
|
|
| Viral ("-vi(r)-") |
|
|
| Bacterial ("-ba(c)-") |
|
Human ("-bacu-")
|
|
|
|
Mouse ("-baco-")
|
|
|
|
|
|
|
|
Humanized ("-bazu-")
|
|
|
|
| Toxin ("-tox(a)-") |
|
|
|
|
|
(what is this?) (verify)
